Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-05-06
2008-05-06
Weber, Jon (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S011400, C530S317000
Reexamination Certificate
active
10006562
ABSTRACT:
The invention provides a composition and a method for preventing or ameliorating the causes of chronic allograft rejection of a donor organ by a transplant recipient. The method includes concomitant administration to the allograft recipient of therapeutically effective amounts of cyclosporin and 2-chlorodeoxyadenosine. The composition comprises a combination of these two immunosuppressive drugs in therapeutically effective amounts suitable for the practice of the method.
REFERENCES:
Nawrocki et al., Transplantation Proceedings, vol. 28, No. 6, pp. 3538-3539, 1996.
Schmid et al., Eur. Surg. Res., vol. 30, pp. 61-68, 1998.
Cramer et al., Transplantation Proceedings, vol. 29, p. 616, 1997.
Cramer, D.V. et al., “2-Chlorodeoxyadenosine in Combination With Cyclosporine Inhibits the Development of Transplant Arteriosclerosis in Rat Cardiac Allografts,”Transplantation Proceedings, 29:616 (1997).
Demetris, A.J. et al., “Analysis of Chronic Rejection and Obliterative Arteriopathy,”American Journal of Pathology, vol. 150, No. 2: 563-578 (1997).
Häyry, P., “Pathophysiology of Chronic Rejection,”Transplantation Proceedings, vol. 28, No. 6, Suppl 1, 7-10 (1996).
Häyry, P. et al., “Towards Understanding the Pathophysiology of Chronic Rejection,”Clin Investig70:780-90 (1992).
Nawrocki, G. et al., “Prolongation of Cardiac Allograft Survival in Rats Following Combination Treatment With 2-Chloro-2'-Deoxyadenosine and Cyclosporine,”Transplantation Proceedings, vol. 28, No. 6 pp. 3538-3539 (1996).
Nowaczyk, M. et al., “2-Chlorodeoxyadenosine: Lack of Synergism with Cyclosporine A and Tacrolimus (FK506),”Arch Immunol Ther Exp.Warsz 43(5-6):329-32 (1995).
Orosz, C. G. et al., “Chronic Remodeling Pathology in Grafts,”Current Opinion in Immunology9:676-680 (1997).
Rao, V. K., “Posttransplant Medical Complications,”Surgical Clinics of North Americavol. 78 No. 1: 113-132 (1998).
Schmid, T. et al., “2-Chlorodeoxyadenosine in Combination with Cyclosporine Prevents Rejection After Allogenic Small Bowel Transplantation”Transplantation Proceedings, vol. 26 No. 3: 1614 (1994).
Schmid, T. et al., “2-Chlorodeoxyadenosine in Combination with Low-Dose Cyclosporine Prevents Rejection After Allogenic Heart and Liver Transplantation in the Rat,”Eur Surg Res30:61-68 (1998).
Schmid, T. et al., “Histologic Pattern of Small Bowel Allograft Rejection in the Rat,”Gastroenterologyvol. 96 No. 6, pp. 1529-1532 (1989).
Wu, G.D. et al., “FK 506 Inhibits the Development of Transplant Arteriosclerosis,”Transplantation Proceedingsvol. 23, No. 6 pp. 3272-3274 (1991).
Häyry, P. et al., “Molecular Biology of Chronic Rejection and Predictive Value of Biopsies.” InSolid Organ Transplant Rejection Mechanisms, Pathology, and Diagnosis, Kim Solez et al., eds. (NY: Marcel Dekker, Inc.), pp. 77-106 (1996).
Supplementary European Search Report Dated Feb. 8, 2005, Application No. EP 02 80 4721.
Aranda JM Jr, Hill J., Cardiac transplant vasculopathy. Chest. Dec. 2000;118(6):1792-800.
Bueno V, Pestana JO. The role of CD8+ T cells during allograft rejection. Braz J Med Biol Res. Nov. 2002;35(11):1247-58.
Chandraker A, Azuma H, Nadeau K, Carpenter CB, Tilney NL, Hancock WW, Sayegh MH. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection.J Clin Invest. Jun. 1, 1998;101(11):2309-18.
Choy JC, Kerjner A, Wong BW, McManus BM, Granville DJ. Perforion mediates endothelial cell death and resultant transplant vascular disease in cardiac allografts. Am J Pathol. Jul. 2004;165(1):127-33.
Demetris, et al., Pathophysiology of Chronic Allograft Rejection CME, Mar. 29, 2000, http://www.medscape.com/viewprogram/336—pnt, visited Jul. 21, 2005, p. 1-71.
Fischbein MP, Yun J, Laks H, Irie Y, Fishbein MC, Bonavida B, Ardehali A. Role of CD8+ lymphocytes in chronic rejection of transplanted hearts. J Thorac Cardiovasc Surg. Apr. 2002;123(4):803-9.
Grieb P, Ryba M, Janczewski W, Sawicki J, Jagielski J, Andrychowski J. 2-Chloro-2'-deoxyadenosine (2-CdA) combined with cyclosporine A successfully prevents rejection of fetal brain stem allograft in rabbits. Arch Immunol Ther Exp (Warsz). 1994;42(1):43-6.
He C, Schenk S, Zhang Q, Valujskikh A, Bayer J, Fairchild RL, Heeger PS. Effects of T cell frequency and graft size on transplant outcome in mice. J Immunol. Jan. 1, 2004;172(1):240-7.
Hollenberg SM, Klein LW, Parrillo JE, Scherer M, Burns D, Tamburro P, Oberoi M, Johnson MR, Costanzo MR. Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death. Circulation. Dec. 18, 2001;104(25):3091-6.
Kobashigawa J. What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy? Curr Control Trials Cardiovasc Med. 2000;1(3):166-171.
Knoop C, Haverich A, Fischer S. Immunosuppressive therapy after human lung transplantation. Eur Respir J. Jan. 2004;23(1):159-71.
Koh KP, Wang Y, Yi T, Shiao SL, Lorber MI, Sessa WC, Tellides G, Pober JS. T cell-mediated vascular dysfunction of human allografts results from IFN-gamma dysregulation of NO synthase. J Clin Invest. Sep. 2004;114(6):846-56.
Kouwenhoven EA, IJzermans JN, de Bruin RW. Etiology and pathophysiology of chronic transplant dysfunction. Transpl Int. 2000;13(6):385-401.
Mehra MR, Ventura HO, Smart FW, Stapleton DD, Collins TJ, Ramee SR, Murgo JP, White CJ. New developments in the diagnosis and management of cardiac allograft vasculopathy. Tex Heart Inst J. 1995;22(2):138-44.
Oberhuber G, Schmid T, Thaler W, Kaltenbacher A, Schirmer M, Liliemark J, Herbst P, Geisen F, Margreiter R, Konwalinka G. Evidence that 2-chlorodeoxyadenosine in combination with cyclosporine prevents rejection after allogeneic small bowel transplantation. Transplantation. Sep. 27, 1994;58(6):743-5.
Shapiro R. Low toxicity immunosuppressive protocols in renal transplantation. Keio J Med. Mar. 2004;53(1):18-22.
Shi C, Lee WS, He Q, Zhang D, Fletcher DL Jr, Newell JB, Haber E. Immunologic basis of transplant-associated arteriosclerosis. Proc Natl Acad Sci U S A. Apr. 30, 1996;93(9):4051-6.
Slachta CA, Jeevanandam V, Goldman B, Lin WL, Platsoucas CD. Coronary arteries from human cardiac allografts with chronic rejection contain oligoclonal T cells: persistence of identical clonally expanded TCR transcripts from the early post-transplantation period (endomyocardial biopsies) to chronic rejection (coronary arteries). J Immunol. Sep. 15, 2000:165(6):3469-83.
Adams, A.B., et al., Conventional immunosuppression and co-stimulation blockade. Philos Trans R Soc Lond B Biol Sci. May 29, 2001;356(1409):703-5.
Iwakoshi NN, et al., Skin allograft maintenance in a new synchimeric model system of tolerance. J Immunol. Dec. 1. 2001;167(11):6623-30.
Sho, M., et al., New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs. Ann Surg. Nov. 2002;236(5):667-75.
Cramer Donald V.
Salomon Daniel R.
Mirick O'Connell DeMallie & Lougee LLP
Mohamed Abdel A
The Scripps Research Institute
Weber Jon
Zimmerman Roger P.
LandOfFree
Composition and method for treating chronic allograft rejection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for treating chronic allograft rejection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for treating chronic allograft rejection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3922407